A 3-Year, State of the Art, Observational Study of Fingolimod in Patients with Multiple Sclerosis for Patient Management in Daily Clinical Practice (PANGAEA 2.0)

Trial Profile

A 3-Year, State of the Art, Observational Study of Fingolimod in Patients with Multiple Sclerosis for Patient Management in Daily Clinical Practice (PANGAEA 2.0)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms PANGAEA-2
  • Sponsors Novartis
  • Most Recent Events

    • 27 Jun 2017 Comparison of baseline data from two studies (PANGAEA and PANGAEA 2.0) presented at the 3rd Congress of the European Academy of Neurology
    • 04 May 2016 New trial record
    • 21 Apr 2016 Baseline results (n=300) were presented at the 68th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top